Janssen Pharms., Inc. v. Teva Pharms. USA, Inc. – 2025 Q3

Nature of the Case and Issue(s) Presented: Invega Sustenna® is a long-acting injectable antipsychotic medication indicated for the treatment of schizophrenia in adults. The ’906 patent addresses the problem of noncompliance with antipsychotic medication by claiming a treatment regimen which uses a long-acting, injectable formulation of paliperidone palmitate that requires less-frequent administration than oral medication….
By: Robins Kaplan LLP